CD147, a tumor‐associated antigen, has been reported to be an important pro‐tumorigenic factor and to participate in multi‐temporal and multi‐stage tumor development.[17, 19, 27, 28, 29] In this study, the di‐methylation of CD147 at Lys148, which is catalyzed by the methyltransferase NSD2, was identified as a new tumor biomarker for NSCLC. The gene discussed is NSD2; the disease is non-small cell lung carcinoma.